American Journal of Drug and Alcohol Abuse 2015;41(6):498-507. [doi: 10.3109/00952990.2015.1044605]
Arthur N. Westover, MD, MS (University of Texas Southwestern Medical Center, TX Node), T. Michael Kashner, PhD (University of Texas Southwestern Medical Center, TX Node), Theresa M. Winhusen, PhD (University of Cincinnati College of Medicine, OV Node), Richard M. Golden, PhD (University of Texas at Dallas), Paul A. Nakonezny, PhD (University of Texas Southwestern Medical Center, TX Node), Bryon H. Adinoff, MD (University of Texas Southwestern Medical Center, TX Node), Steven S. Henley, MS (Martingale Research Corporation).
Traditional approaches to subgroup analyses that test each moderating factor as a separate hypothesis can lead to erroneous conclusions due to the problems of multiple comparisons, model misspecification, and multicollinearity. This study aimed to demonstrated a novel, systematic approach to subgroup analyses that avoids these pitfalls. A Best Approximating Model (BAM) approach that identifies multiple moderators and estimates their simultaneous impact on treatment effect sizes was applied to a randomized, controlled, 11-week, double-blind efficacy trial on smoking cessation of adult smokers with attention-deficit/hyperactivity disorder (ADHD), randomized to either OROS-methylphenidate (n=127) or placebo (n=128) and treated with nicotine patch (National Drug Abuse Treatment Clinical Trials Network protocol CTN-0029). Binary outcomes measures were prolonged smoking abstinence and point prevalence smoking abstinence.
Although the original clinical trial data analysis showed no treatment effect on smoking cessation, the BAM analysis showed significant subgroup effects for the primary outcome of prolonged smoking abstinence: (1) lifetime history of substance use disorders, and (2) more severe ADHD symptoms. A significant subgroup effect was also shown for the secondary outcome of point prevalence smoking abstinence -- age 18-29 years.
Conclusions: The BAM analysis resulted in different conclusions about subgroup effects compared to a hypothesis-driven approach. These divergent findings underscore the need for investigators to consider more advanced statistical methods to better analyze subgroup effect sizes. By examining moderator independence and avoiding multiple testing, BAMs have the potential to better identify and explain how treatment effects vary across subgroups in heterogeneous patient populations, thus providing better guidance to more effectively match individual patients with specific treatments. (Article (Peer-Reviewed), PDF, English, 2015)
Keywords: Attention Deficit Hyperactivity Disorder (ADHD) | CTN platform/ancillary study | Osmotic-Release Methylphenidate (OROS-MPH) | Pharmacological therapy | Statistical analysis | Statistical models | Smoking | American Journal of Drug and Alcohol Abuse (journal)
Document No: 1151, PMID: 26065433, PMCID: PMC4817346.
Submitted by CTN Dissemination Librarians, 6/19/2015.